Esberitox tablets 3.2 mg. №40

Description

Esberitox tablets Storage
active substances: 1 tablet contains 3.2 mg of dry extract (4-9: 1) from a mixture of raw materials: rhizomes of dye baptism (Bapticia tinctoria L); Echinacea purpurea Moench root; roots of Echinacea pallida (Echinacea pallida Nutt); young shoots and leaves of thuja (Thuja occidentalis L.).

Extractant: ethanol 30% (v / v);

excipients: lactose; macrogol 6000; magnesium stearate; saccharose.

Esberitox tablets Dosage form
Tablets.

Main physical and chemical properties: from beige to light brown, round, slightly convex tablets on both sides, with a diameter of about 9 mm, a thickness of about 4 mm, without the risk of separation.

Pharmacotherapeutic group
Other immunostimulants. ATX code L03A X.

Pharmacological properties

Pharmacodynamics.

In various preclinical models at different sites of action Esberitox demonstrates stimulation of the immune system.

In the case of viral colds, clinical stimulation of the body’s defenses is manifested in the relief of symptoms and reduction of the duration of the disease.

Pharmacokinetics.

It is impossible to clearly attribute the relevant pharmacodynamic results to the separately identified components, as Esberitox tablets are a complex mixture of several herbal substances. There is no information on the pharmacokinetics of the drug.

Esberitox tablets Indication
To strengthen the body’s resistance as a supportive therapy in the complex treatment of viral colds.

Contraindication
Hypersensitivity to the active substances or to any of the excipients. The drug should not be used in patients with progressive systemic diseases (tuberculosis and sarcoidosis); in autoimmune diseases (collagenosis, multiple sclerosis); in immunodeficiency conditions (AIDS, HIV infection); in immunosuppressive conditions caused by the use of cytostatic drugs or immunosuppressants, for example, after transplantation; in hematological diseases (leukemia, agranulocytosis).

Interaction with other medicinal products and other forms of interaction
Interaction with other drugs is unknown.

Relevant studies on the interaction of the drug with other drugs have not been conducted.

Features of application
If symptoms persist or persist for more than 10 days, or if shortness of breath, fever, purulent, or bloody discharge occurs, consult a physician.

Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, sucrose isomaltase deficiency, lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Use during pregnancy or breastfeeding.

There are no adequate data from the use of Esberitox in pregnant women. Reproductive toxicity of the drug has not been sufficiently studied in animal studies. Because the safety of Esberitox tablets during pregnancy has not been established, the drug should be taken after careful evaluation of the benefit to the mother / risk to the fetus (child).

There is no information on the excretion of certain components of Esberitox in breast milk and their adverse effects on breastfed infants. Warning: Esberitox, tablets should not be taken during breastfeeding.

The ability to influence the speed of reaction when driving a car or other machinery.

Unknown.